Company: CDLX
Filing Date: 2025-04-03
Form Type: ARS
Source: 0001666071-25-000048
Chunk: 105

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: ARS
Chunk 105
---
 — (40,000) Other comprehensive loss — — — 5,112 — 5,112 Net loss — — — — (465,264) (465,264) Balance – December 31, 2022 33,477 $ 9 $ 1,182,568 $ 5,598 $ (976,570) $ 211,605 See notes to the consolidated financial statements 68

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands) Year Ended December 31, 2024 2023 2022 Operating activities Net Loss $ (189,304) $ (134,702) $ (465,264) Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Credit loss expense 6,106 1,704 2,399 Depreciation and amortization 25,689 26,460 37,544 Amortization of financing costs charged to interest expense 1,633 1,648 1,595 Amortization of right-of-use asset 2,187 3,055 6,196 Impairment of goodwill and intangible assets 131,595 70,518 453,288 Loss on divestiture — 6,550 — Gain on debt extinguishment (13,017) — — Stock-based compensation expense 40,367 40,980 44,686 Change in contingent consideration 210 1,246 (128,174) Other non-cash expense (income), net 1,481 (4,170) 6,589 Income tax benefit — — (1,446) Change in operating assets and liabilities: Accounts receivable and contracts assets, net 12,497 (7,725) (4,546) Prepaid expenses and other assets 1,360 2,492 535 Accounts payable 499 239 (893) Other accrued expenses (6,644) (7,492) (9,516) Partner Share liability (16,350) 405 1,721 Customer Incentive liability (7,133) (1,393) 1,382 Net cash used in operating activities (8,824) (185) (53,904) Investing activities Acquisition of property and equipment (1,562) (667) (1,171) Acquisition of patents — — (175) Capitalized software development costs (17,736) (11,